Scorpius Holdings Executes First cGMP Microbial Batches

• Scorpius Holdings Inc. completes first cGMP microbial batches at San Antonio facility.

Scorpius Holdings Inc. has successfully executed its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This marks the beginning of the company’s support for clinical manufacturing programs, with future commercial activities in sight.

The San Antonio facility has already attracted significant interest, resulting in a backlog of client program bookings. This achievement demonstrates Scorpius’ ability to meet stringent regulatory and client-driven standards essential for the contract manufacturing of microbial biologics. The company plans to continue cGMP activities throughout the remainder of the year.

Jeff Wolf, CEO of Scorpius Holdings, commented, “We are thrilled to have successfully completed our first cGMP microbial batches at the San Antonio facility. This milestone is a result of the dedication and collaboration among Scorpius’ manufacturing, process development, quality, and operations teams. The successful execution is a testament to the robust systems we have built and marks another step forward in our commitment to U.S. based cGMP activities for both current and future Scorpius clients.”